Jobevne (Bevacizumab-nwgd): Transforming Cancer Treatment With Accessibility and Affordability Across Multiple Indications
DOI:
https://doi.org/10.63501/br6fwx89Keywords:
Cancer Treatment, Bevacizumab-nwgd, Therapeutic InnovationAbstract
Jobevne (Bevacizumab-nwgd) is a recently FDA-approved biosimilar to Avastin, developed by Biocon Biologics for multiple oncology indications. It targets vascular endothelial growth factor (VEGF), a key driver of angiogenesis in cancer, offering effective treatment for conditions such as metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and advanced ovarian cancer. Clinical trials confirm its safety and efficacy comparable to Avastin, while its lower cost enhances global accessibility. As the sixth biosimilar to Avastin, Jobevne represents a critical advancement in making high-quality cancer therapies more affordable, maintaining therapeutic equivalence with reduced financial burden for patients.
References
References
[1]. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-249. [PubMed] [American Cancer Society] [Google Scholar]
[2]. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011 Sep;12(10):933–80. [PubMed] [The Lancet] [Google Scholar]
[3]. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. [PubMed] [Cell Press] [Google Scholar]
[4]. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May;3(5):391–400. [PubMed] [Nature] [Google Scholar]
[5]. Sullivan R, Pramesh CS, Booth CM. Cancer patients need better care, not just more technology. Nature. 2017 Sep 19;549(7672):325–8. [PubMed] [The BMJ] [Google Scholar]
[6]. U.S. Food and Drug Administration. FDA approves Jobevne (bevacizumab-nwgd), a biosimilar to Avastin. FDA News Release. 2025 Apr.. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
[7]. Kang J. FDA approves bevacizumab biosimilar Jobevne. Cancer Ther Advis. 2025 Apr 11. Available from: https://www.cancertherapyadvisor.com/news/fda-approves-bevacizumab-biosimilar-jobevne/
[8]. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 20;26(12):2013–9. Doi: 10.1200/JCO.2007.14.9930.[PubMed] [ASCO Publications] [Google Scholar]
[9]. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542–50. Doi: 10.1056/NEJMoa061884.. [PubMed] [NEJM] [Google Scholar]
[10]. Drugs.com. Jobevne: Package Insert / Prescribing Information. Available from: https://www.drugs.com/pro/jobevne.html#s-34092-7